ANGO · Angiodynamics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.42M | $79.43M | $75.71M | $72.84M | $72.00M | $67.49M | $79.07M | $75.18M | $78.68M | $85.43M |
| Cost of Revenue | $36.94M | $34.65M | $33.85M | $32.94M | $33.15M | $30.77M | $38.81M | $39.32M | $38.62M | $40.35M |
| Gross Profit | $41.48M | $44.78M | $41.86M | $39.91M | $38.86M | $36.72M | $40.26M | $35.86M | $40.06M | $45.08M |
| R&D | $7.08M | $7.77M | $6.42M | $6.43M | $6.91M | $6.29M | $8.66M | $8.19M | $7.94M | $6.84M |
| SG&A | $10.72M | $10.15M | $12.55M | $10.39M | $10.49M | $10.97M | $9.29M | $10.58M | $10.86M | $10.84M |
| Total Operating Expenses | $54.43M | $50.91M | $52.51M | $51.00M | $48.83M | $49.82M | $53.38M | $242.41M | $52.87M | $53.19M |
| D&A | - | - | $6.02M | - | - | $6.79M | - | - | $6.69M | - |
| Operating Income | ($12.95M) | ($6.13M) | ($10.66M) | ($11.09M) | ($9.97M) | ($13.10M) | ($13.12M) | ($199.90M) | $35.03M | ($8.12M) |
| Interest Expense | - | - | - | - | - | - | ($534.0K) | ($394.0K) | ($119.0K) | $684.0K |
| Income Tax | $12.0K | ($5.0K) | $65.0K | ($110.0K) | ($2.0K) | $133.0K | $16.43M | ($12.00M) | ($11.02M) | ($565.0K) |
| Net Income | ($8.08M) | ($6.35M) | ($10.90M) | ($10.74M) | ($4.41M) | ($12.80M) | ($29.05M) | ($187.74M) | $45.88M | ($13.00M) |
| EPS - Basic | ($0.19) | ($0.15) | ($0.26) | ($0.26) | ($0.11) | ($0.31) | ($0.72) | ($4.67) | $1.15 | ($0.21) |
| EPS - Diluted | ($0.19) | ($0.15) | ($0.26) | ($0.26) | ($0.11) | ($0.31) | ($0.72) | ($4.67) | $1.15 | ($0.21) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.81M | $41.64M | $38.76M | $55.89M | $44.76M | $55.01M | $76.06M | $78.45M | $57.59M | $44.62M |
| Accounts Receivable | $45.55M | $44.43M | $42.64M | $42.89M | $43.47M | $39.56M | $43.61M | $49.48M | $49.76M | $52.83M |
| Inventory | $58.58M | $65.57M | $62.26M | $62.01M | $63.10M | $64.70M | $60.62M | $58.07M | $59.97M | $55.33M |
| Accounts Payable | $29.11M | $35.39M | $31.88M | $33.29M | $30.27M | $31.27M | $37.75M | $35.15M | $24.81M | $40.45M |
| Current Assets | $155.55M | $161.35M | $156.66M | $168.32M | $172.27M | $172.59M | $193.25M | $196.91M | $175.47M | $163.54M |
| Total Assets | $260.68M | $269.68M | $265.64M | $280.14M | $285.42M | $293.63M | $317.67M | $324.84M | $493.95M | $532.64M |
| Current Liabilities | $66.07M | $71.96M | $68.28M | $76.20M | $77.97M | $76.70M | $91.16M | $85.87M | $57.45M | $83.83M |
| Long-term Debt | - | - | - | - | - | - | $0 | - | - | $49.82M |
| Total Liabilities | $87.32M | $93.35M | $86.79M | $97.17M | $99.55M | $97.05M | $112.08M | $106.14M | $66.14M | $154.34M |
| Stockholders' Equity | $173.36M | $176.33M | $178.85M | $182.97M | $185.87M | $196.58M | $205.59M | $218.70M | $427.80M | $378.30M |
| Retained Earnings | ($454.53M) | ($446.45M) | ($440.10M) | ($429.20M) | ($423.15M) | ($408.00M) | ($395.20M) | ($381.75M) | ($164.97M) | ($210.85M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($15.91M) | - | - | ($18.25M) | - | - | ($25.90M) | - |
| Investing Cash Flow | - | - | ($1.55M) | - | - | ($2.40M) | - | - | $98.44M | - |
| Financing Cash Flow | - | - | $143.0K | - | - | ($509.0K) | - | - | ($59.59M) | - |
| CapEx | - | - | $731.0K | - | - | $1.09M | - | - | $791.0K | - |
| Free Cash Flow | - | - | ($16.64M) | - | - | ($19.34M) | - | - | ($26.69M) | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 52.9% | 56.4% | 55.3% | 54.8% | 54.0% | 54.4% | 50.9% | 47.7% | 50.9% | 52.8% |
| Operating margin | -16.5% | -7.7% | -14.1% | -15.2% | -13.9% | -19.4% | -16.6% | -265.9% | 44.5% | -9.5% |
| EBITDA margin | - | - | -6.1% | - | - | -9.4% | - | - | 53.0% | - |
| Net margin | -10.3% | -8.0% | -14.4% | -14.7% | -6.1% | -19.0% | -36.7% | -249.7% | 58.3% | -15.2% |
| Free cash flow margin | - | - | -22.0% | - | - | -28.7% | - | - | -33.9% | - |
| FCF / Net income | - | - | 1.53 | - | - | 1.51 | - | - | -0.58 | - |
| R&D / Revenue | 9.0% | 9.8% | 8.5% | 8.8% | 9.6% | 9.3% | 10.9% | 10.9% | 10.1% | 8.0% |
| SG&A / Revenue | 13.7% | 12.8% | 16.6% | 14.3% | 14.6% | 16.3% | 11.7% | 14.1% | 13.8% | 12.7% |
| Effective tax rate | - | - | - | - | - | - | - | - | -31.6% | - |
| Return on assets | -3.1% | -2.4% | -4.1% | -3.8% | -1.5% | -4.4% | -9.1% | -57.8% | 9.3% | -2.4% |
| Return on equity | -4.7% | -3.6% | -6.1% | -5.9% | -2.4% | -6.5% | -14.1% | -85.8% | 10.7% | -3.4% |
| Return on invested capital | - | - | - | - | - | - | -5.0% | - | - | -1.5% |
| Liquidity | ||||||||||
| Current ratio | 2.35 | 2.24 | 2.29 | 2.21 | 2.21 | 2.25 | 2.12 | 2.29 | 3.05 | 1.95 |
| Quick ratio | 1.47 | 1.33 | 1.38 | 1.40 | 1.40 | 1.41 | 1.46 | 1.62 | 2.01 | 1.29 |
| Cash ratio | 0.57 | 0.58 | 0.57 | 0.73 | 0.57 | 0.72 | 0.83 | 0.91 | 1.00 | 0.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | 0.00 | - | - | 0.13 |
| Debt / Assets | - | - | - | - | - | - | 0.00 | - | - | 0.09 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | 24.6x | 507.4x | -294.4x | -11.9x |
| Equity multiplier | 1.50 | 1.53 | 1.49 | 1.53 | 1.54 | 1.49 | 1.55 | 1.49 | 1.15 | 1.41 |
| Liabilities / Assets | 0.33 | 0.35 | 0.33 | 0.35 | 0.35 | 0.33 | 0.35 | 0.33 | 0.13 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.30 | 0.29 | 0.29 | 0.26 | 0.25 | 0.23 | 0.25 | 0.23 | 0.16 | 0.16 |
| Inventory turnover | 0.63 | 0.53 | 0.54 | 0.53 | 0.53 | 0.48 | 0.64 | 0.68 | 0.64 | 0.73 |
| Days sales outstanding | 212d | 204d | 206d | 215d | 220d | 214d | 201d | 240d | 231d | 226d |
| Days inventory outstanding | 579d | 691d | 671d | 687d | 695d | 768d | 570d | 539d | 567d | 500d |
| Days payable outstanding | 288d | 373d | 344d | 369d | 333d | 371d | 355d | 326d | 234d | 366d |
| Cash conversion cycle | 503d | 522d | 533d | 533d | 582d | 611d | 416d | 453d | 563d | 360d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 7.0x | - |
| P / B | 2.7x | 2.9x | 2.4x | 2.3x | 2.0x | 1.5x | 1.2x | 1.0x | 0.8x | 1.0x |
| P / S | 6.1x | 6.5x | 5.6x | 5.7x | 5.3x | 4.5x | 3.2x | 2.9x | 4.1x | 4.4x |
| EV / EBITDA | - | - | - | - | - | - | - | - | 6.3x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.9% | 9.0% | 12.2% | -7.9% | -4.2% | -14.2% | -7.4% | -6.9% | -3.5% | 17.4% |
| Revenue CAGR (3y) | -1.0% | -2.4% | -2.4% | 0.0% | -0.9% | -4.3% | 2.8% | 1.8% | 3.9% | 6.9% |
| Revenue CAGR (5y) | 2.0% | 1.8% | 1.5% | 0.8% | 0.6% | 0.4% | -2.9% | -2.7% | -1.6% | -0.3% |
| Gross profit growth (YoY) | 6.7% | 12.2% | 14.0% | -0.9% | 8.4% | -8.3% | -10.7% | -11.5% | -5.3% | 11.2% |
| Operating income growth (YoY) | -29.8% | 44.8% | 18.6% | 15.4% | 95.0% | - | -61.7% | -2139.0% | - | 6.5% |
| Net income growth (YoY) | -83.4% | 40.9% | 14.8% | 63.0% | 97.7% | - | -123.4% | -1879.3% | - | -55.7% |
| EPS growth (YoY) | -72.7% | 42.3% | 16.1% | 63.9% | 97.6% | - | -242.9% | -1845.8% | - | 0.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 14.0% | - | - | 27.5% | - | - | -4.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -6.7% | -3.6% | -9.0% | -11.0% | -15.0% | -54.0% | -45.7% | -45.0% | 3.3% | -10.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-05-31.
Business segments
$292.50M totalMed Device Segment$165.84M · 56.7%
Med Tech Segment$126.65M · 43.3%
Product / service
$250.98M totalMed Device Segment$141.73M · 56.5%
Med Tech Segment$109.25M · 43.5%
Geographic
$334.01M totalUS$250.98M · 75.1%
International$41.52M · 12.4%
Non Us$41.52M · 12.4%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ANGIODYNAMICS INC against the 5 most active filers in the same SIC group.